Jeffrey A. Bluestone
Impact in
- Immunology top 0.01%
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Transplantation top 0.1%
Papers in
- Immunology 381
- T-cell and B-cell Immunology 296
- Immune Cell Function and Interaction 255
- Immunotherapy and Immune Responses 149
- Genetics 120
- Diabetes and associated disorders 109
- Co-authors
- Qizhi Tang (59 shared papers)Theresa L. Walunas (15 shared papers)Deborah J. Lenschow (17 shared papers)Kevan C. Herold (33 shared papers)Benoı̂t L. Salomon (12 shared papers)Craig B. Thompson (14 shared papers)Abul K. Abbas (7 shared papers)Mark S. Anderson (12 shared papers)
- Journals
- The Journal of Immunology (136 papers)The Journal of Experimental Medicine (37 papers)Transplantation (19 papers)Immunity (15 papers)Diabetes (14 papers)
- Partner nations
- United StatesFranceAustralia
In The Last Decade
Jeffrey A. Bluestone
502 papers receiving 70.3k citations
Jeffrey A. Bluestone's Hit Papers
Peers
Comparison fields: 5 of 171
- Immunology 45.7k
- Transplantation 1.7k
- Oncology 13.0k
- Genetics 14.2k
- Endocrinology, Diabetes and Metabolism 5.4k
Countries citing papers authored by Jeffrey A. Bluestone
This map shows the geographic impact of Jeffrey A. Bluestone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey A. Bluestone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey A. Bluestone more than expected).
Fields of papers citing papers by Jeffrey A. Bluestone
This network shows the impact of papers produced by Jeffrey A. Bluestone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey A. Bluestone. The network helps show where Jeffrey A. Bluestone may publish in the future.
Co-authors
The 25 scholars most cited alongside Jeffrey A. Bluestone, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 508 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | CD28/B7 SYSTEM OF T CELL COSTIMULATION Hit paper breakdown → | 1996 | 2307 |
| 2 | CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells Hit paper breakdown → | 2006 | 2152 |
| 3 | CTLA-4 can function as a negative regulator of T cell activation Hit paper breakdown → | 1994 | 1849 |
| 4 | Innate immunity and intestinal microbiota in the development of Type 1 diabetes Hit paper breakdown → | 2008 | 1601 |
| 5 | Identification of a monoclonal antibody specific for a murine T3 polypeptide. Hit paper breakdown → | 1987 | 1523 |
| 6 | The B7 and CD28 receptor families Hit paper breakdown → | 1994 | 1183 |
| 7 | Natural versus adaptive regulatory T cells Hit paper breakdown → | 2003 | 1090 |
| 8 | Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo Hit paper breakdown → | 2009 | 1082 |
| 9 | In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes Hit paper breakdown → | 2004 | 1062 |
| 10 | Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lg Hit paper breakdown → | 1992 | 1005 |
| 11 | Genetics, pathogenesis and clinical interventions in type 1 diabetes Hit paper breakdown → | 2010 | 988 |
| 12 | Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus Hit paper breakdown → | 2002 | 975 |
| 13 | Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis Hit paper breakdown → | 2013 | 934 |
| 14 | THE NOD MOUSE: A Model of Immune Dysregulation Hit paper breakdown → | 2004 | 899 |
| 15 | Complexities of CD28/B7: CTLA-4 Costimulatory Pathways in Autoimmunity and Transplantation Hit paper breakdown → | 2001 | 898 |
| 16 | Type 1 diabetes immunotherapy using polyclonal regulatory T cells Hit paper breakdown → | 2015 | 847 |
| 17 | Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways Hit paper breakdown → | 2008 | 843 |
| 18 | The Foxp3+ regulatory T cell: a jack of all trades, master of regulation Hit paper breakdown → | 2008 | 828 |
| 19 | CTLA-4 ligation blocks CD28-dependent T cell activation. Hit paper breakdown → | 1996 | 690 |
| 20 | CD28 Costimulation: From Mechanism to Therapy Hit paper breakdown → | 2016 | 663 |
About Jeffrey A. Bluestone
Jeffrey A. Bluestone is a scholar working on Immunology, Genetics, Oncology, Radiology, Nuclear Medicine and Imaging and Surgery, having authored 508 papers that have together received 72.1k indexed citations. Recurring topics across this work include T-cell and B-cell Immunology (296 papers), Immune Cell Function and Interaction (255 papers), Immunotherapy and Immune Responses (149 papers), Diabetes and associated disorders (109 papers), Monoclonal and Polyclonal Antibodies Research (71 papers), CAR-T cell therapy research (71 papers), Pancreatic function and diabetes (52 papers) and Cancer Immunotherapy and Biomarkers (41 papers). The work is most often cited by research in Immunology (45.7k citations), Transplantation (1.7k citations), Oncology (13.0k citations), Genetics (14.2k citations) and Endocrinology, Diabetes and Metabolism (5.4k citations). Jeffrey A. Bluestone has collaborated with scholars based in United States, France and Australia. Frequent co-authors include Qizhi Tang, Theresa L. Walunas, Deborah J. Lenschow, Kevan C. Herold, Benoı̂t L. Salomon, Craig B. Thompson, Abul K. Abbas, Mark S. Anderson, Gregory L. Szot and Brian T. Fife. Their work appears in journals such as The Journal of Immunology, The Journal of Experimental Medicine, Transplantation, Immunity and Diabetes.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.